杨源民;陈利娜;瞿水清;邓硕秋;刘慧;王茜;翁小刚;王娅杰;朱晓新;李玉洁;
YANG Yuan-min;CHEN Li-na;QU Shui-qing;DENG Shuo-qiu;LIU Hui;WANG Xi;WENG Xiao-gang;WANG Ya-jie;ZHU Xiao-xin;LI Yu-jie;Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences;Artemisinin Research Center, China Academy of Chinese Medical Sciences;School of Traditional Chinese Medicine, Guangdong Pharmaceutical University;School of Pharmacy, Shanxi Medical University;

• 1:中国中医科学院中药研究所
• 2:中国中医科学院青蒿素研究中心
• 3:广东药科大学中药学院
• 4:山西医科大学药学院

摘要(Abstract)：

新型冠状病毒肺炎(corona virus disease 2019,COVID-19)已给人类生存和社会发展带来深重灾难。新型冠状病毒肺炎导致的急性心肌损伤和心血管系统的慢性损害已引起学术界的广泛关注,"老药新用"是治疗COVID-19重要的近期策略。青蒿素及其衍生物药理活性广泛,近年研究表明其具有明确的心血管保护作用。该文主要从新型冠状病毒(2019 novel coronavirus,2019-nCoV)直接损伤心肌细胞、病毒配体竞争性结合ACE2削弱其心血管保护作用、"细胞因子风暴"继发心肌受损、感染或应激诱发心律失常及心源性猝死、低氧血症致心肌损伤、COVID-19治疗药物相关心脏损害等方面梳理COVID-19心血管损伤发病机制,从青蒿素及其衍生物抗心律失常、抗心肌缺血、抗动脉粥样硬化及增加斑块稳定性等多角度总结青蒿素及其衍生物的心血管保护作用。基于此,结合青蒿素及其衍生物疗效确切的恢复免疫平衡、减轻多器官损伤、广谱抗病毒作用等,分析青蒿素及其衍生物对包括心血管并发症在内的COVID-19多种重要并发症可能发挥的多途径干预作用,以期为通过"老药新用"快速挖掘COVID-19有效治疗药物提供新的线索,也为COVID-19心血管并发症治疗提供新的依据。
Corona virus disease 2019(COVID-19) has brought untold human sufferings and economic tragedy worldwide. It causes acute myocardial injury and chronic damage of cardiovascular system, which has attracted much attention from researchers. For the immediate strategy for COVID-19, "drug repurposing" is a new opportunity for developing drugs to fight COVID-19. Artemisinin and its derivatives have a wide range of pharmacological activities. Recent studies have shown that artemisinin has clear cardiovascular protective effects. This paper summarizes the research progress on the pathogenesis the pathogenesis of COVID-19 in cardiovascular damage by 2019 novel coronavirus(2019-nCoV) virus from myocardial cell injury directly by 2019-nCoV virus,viral ligands competitively bind to ACE2 and then reduce the protective effect of ACE2 on cardiovascular disease, "cytokine storm" related myocardial damage, arrhythmia and sudden cardiac death induced by the infection and stress, myocardial injury by hypoxemia, heart damage side effects from COVID-19 drugs and summarizing the cardiovascular protective effects of artemisinin and its derivatives have activities of anti-arrhythmia, anti-myocardial ischemia, anti-atherosclerosis and plaque stabilization. Then analyzed the possible multi-pathway intervention effects of artemisinin-based drugs on multiple complications of COVID-19 based on its specific immunomodulatory effects, protective effects of tissue and organ damage and broad-spectrum antiviral effect, to provide clues for the treatment of cardiovascular complications of COVID-19, and give a new basis for the therapy of COVID-19 through "drug repurposing".

关键词(KeyWords)： 新型冠状病毒;新型冠状病毒肺炎;心血管疾病;心脏损伤;老药新用;青蒿素;青蒿素衍生物
2019-nCoV;COVID-19;cardiovascular disease;heart injury;drug repurposing;artemisinin;artemisinin derivatives

Abstract:

Keywords:

基金项目(Foundation): 国家自然基金面上项目(81673640);国家自然科学基金特别资助项目(81841001);; 国家“重大新药创制”科技重大专项(2017ZX09301012002,2017ZX09101002-001-001-3)

作者(Author): 杨源民;陈利娜;瞿水清;邓硕秋;刘慧;王茜;翁小刚;王娅杰;朱晓新;李玉洁;
YANG Yuan-min;CHEN Li-na;QU Shui-qing;DENG Shuo-qiu;LIU Hui;WANG Xi;WENG Xiao-gang;WANG Ya-jie;ZHU Xiao-xin;LI Yu-jie;Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences;Artemisinin Research Center, China Academy of Chinese Medical Sciences;School of Traditional Chinese Medicine, Guangdong Pharmaceutical University;School of Pharmacy, Shanxi Medical University;

Email:

DOI: 10.19540/j.cnki.cjcmm.20200828.601

参考文献(References)：

• [1]PAULES C I,MARSTON H D,FAUCI A S.Coronavirus infections-more than just the common cold[J].J Am Med Assoc,2020,doi:10.1001/jama.2020.0757．
• [2]丁金宏，程晨，万芊．中国新冠肺炎平均病死率演变特征分析[J]．人口与社会，2020,36(2):1．
• [3]SHI S,QIN M,SHEN B,et al.Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan,China[J].J Am Med Assoc Cardiol,2020,5(7):802．
• [4]ZHOU F,YU T,DU R,et al.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan,China:a retrospective cohort study[J].Lancet,2020,395 (10229):1054．
• [5]中华医学会心血管病学分会，中华心血管病杂志编辑委员会．新型冠状病毒肺炎疫情防控期间心血管急危重症患者临床处理原则的专家共识[J]．中华心血管病杂志，2020,48(3):189．
• [6]中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组．新型冠状病毒肺炎流行病学特征分析[J]．中华流行病学杂志，2020,41(2):145．
• [7]邹全明，李海波，曾浩．新型冠状病毒肺炎治疗药物的研究现状及对策建议[J]．第三军医大学学报，2020,42(9):861．
• [8]PANTZIARKA P,PIRMOHAMED M,MIRZA N.New uses for old drugs[J].Brit Med J,2018,361:k2701．
• [9]ZUMLA A,CHAN J F,AZHAR E I,et al.Coronaviruses-drug discovery and therapeutic options[J].Nat Rev Drug Discov,2016,15(5):327．
• [10]GORDON C J,TCHESNOKOV E P,FENG J Y,et al.The antiviral compound remdesivir potently inhibits RNA-dependent RNApolymerase from Middle East respiratory syndrome coronavirus[J].J Biol Chem,2020,295(15):4773．
• [11]WANG M,CAO R,ZHANG L,et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV) in vitro[J].Cell Res,2020,30(3):269．
• [12]CHU C,CHENG V,HUNG I,et al.Role of lopinavir/ritonavir in the treatment of SARS:initial virological and clinical findings[J].Thorax,2004,59(3):252．
• [13]World Health Organization.World malaria report 2019[EB/OL].(2019-12-04)[2020-07-20].https://www.who.int/malaria/publications/world_malaria_report/en/．
• [14]刘桂梅，蔡楠，谢静，等．青蒿素及其衍生物用于治疗新型冠状病毒肺炎的探讨[J]．药物评价研究，2020,43(4):606．
• [15]CAO T H,JIN S G,FEI D S,et al.Artesunate protects against sepsis-induced lung injury via heme oxygenase-1 modulation[J].Inflammation,2016,39(2):651．
• [16]CHENG Z,QI R,LI L,et al.Dihydroartemisinin ameliorates sepsis-induced hyperpermeability of glomerular endothelium via up-regulation of occludin expression[J].Biomed Pharmacother,2018,99:313．
• [17]CLERKIN K J,FRIED J A,RAIKHELKAR J,et al.COVID-19and cardiovascular disease[J].Circulation,2020,141 (20):1648．
• [18]WANG D,HU B,HU C,et al.Clinical characteristics of 138hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,China[J].J Am Med Assoc,2020,323(11):1061．
• [19]CHEN N,ZHOU M,DONG X,et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study[J].Lancet,2020,395(10223):507．
• [20]HUI H,ZHANG Y,YANG X,et al.Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia[J].Med Rxiv,2020,doi:https://doi.org/10.1101/2020.02.24.20027052．
• [21]彭昱东，孟凯，官红权，等．心血管病患者感染新型冠状病毒肺炎112例临床特点及转归[J]．中华心血管病杂志，2020,48(6):450．
• [22]ABOUGHDIR M,KIRWIN T,ABDUL KHADER A,et al.Prognostic value of cardiovascular biomarkers in COVID-19:a review[J].Viruses,2020,12(5):527．
• [23]GUO T,FAN Y,CHEN M,et al.Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)[J].J Am Med Assoc Cardiol,2020,5(7):1．
• [24]LI S S,CHENG C W,FU C L,et al.Left ventricular performance in patients with severe acute respiratory syndrome:a 30-day echocardiographic follow-up study[J].Circulation,2003,108(15):1798．
• [25]WU Q,ZHOU L,SUN X,et al.Altered lipid metabolism in recovered SARS patients twelve years after infection[J].Sci Rep,2017,7(1):9110．
• [26]GUAN W J,NI Z Y,HU Y,et al.Clinical characteristics of coronavirus disease 2019 in China[J].N Engl J Med,2020,382(18):1708．
• [27]HUANG C,WANG Y,LI X,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J].Lancet,2020,395(10223):497．
• [28]XU Z,SHI L,WANG Y,et al.Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J].Lancet Respir Med,2020,8(4):420．
• [29]ZHANG Y H,ZHANG Y H,DONG X F,et al.ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response[J].Inflamm Res,2015,64(3/4):253．
• [30]SRIRAMULA S,CARDINALE J P,LAZARTIGUES E,et al.ACE2 overexpression in the paraventricular nucleus attenuates angiotensinⅡ-induced hypertension[J].Cardiovasc Res,2011,92(3):401．
• [31]HOFFMANN M,KLEINE-WEBER H,SCHROEDER S,et al.2019-nCoV cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J].Cell,2020,181(2):271．
• [32]OUDIT G Y,KASSIRI Z,JIANG C,et al.SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS[J].Eur J Clin Invest,2009,39(7):618．
• [33]HUANG W C,CHOU R H,CHANG C C,et al.Systemic inflammatory response syndrome is an independent predictor of one-year mortality in patients with acute myocardial infarction[J].Acta Cardiol Sin,2017,33(5):477．
• [34]GUAN W J,NI Z Y,HU Y,et al.Clinical characteristics of coronavirus disease 2019 in China[J].N Engl J Med,2020,382(18):1708．
• [35]ZHANG Y,XIAO M,ZHANG S,et al.Coagulopathy and antiphospholipid antibodies in patients with Covid-19[J].N Engl JMed,2020,382(17):e38．
• [36]KOLLIAS A,KYRIAKOULIS K G,DIMAKAKOS E,et al.Thromboembolic risk and anticoagulant therapy in COVID-19 patients:emerging evidence and call for action[J].Br J Haematol,2020,189(5):846．
• [37]KLOK F A,KRUIP M,VAN DER MEER N J M,et al.Incidence of thrombotic complications in critically ill ICU patients with COVID-19[J].Thromb Res,2020,191:145．
• [38]KLOK F A,KRUIP M,VAN DER MEER N J M,et al.Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19:an updated analysis[J].Thromb Res,2020,191:148．
• [39]LEE A,CONNORS J,KREUZIGER L,et al.COVID-19 and coagulopathy:frequently asked questions[EB/OL].(2020-07-20)[2020-07-29].https://www.hematology.org/covid-19/covid-19-and-coagulopathy
• [40]YU C M,WONG R S,WU E B,et al.Cardiovascular complications of severe acute respiratory syndrome[J].Postgrad Med J,2006,82(964):140．
• [41]LIU P P,BLET A,SMYTH D,LI H.The Science underlying COVID-19:implications for the cardiovascular system[J].Circulation,2020,142(1):68．
• [42]刘梦露，刘华龙，洪葵．儿茶酚胺与应激性心肌病发病机制的研究进展[J]．中国心脏起搏与心电生理杂志，2019,33(2):160．
• [43]ZHENG Y Y,MA Y T,ZHANG J Y,et al.COVID-19 and the cardiovascular system[J].Nat Rev Cardiol,2020,17(5):259．
• [44]杨铭耀，高杨杨，邹炎洁，等．超说明书应用洛匹那韦/利托那韦治疗新型冠状病毒肺炎的临床药学指引[J]．中国医院药学杂志，2020,40(6):617．
• [45]郭栋，郭万刚，刘鹏云，等．新型冠状病毒感染的心脏表现[J]．心脏杂志，2020,32(1):75．
• [46]JANKELSON L,KARAM G,BECKER M L,et al.QT prolongation,torsades de pointes,and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19:a systematic review[J].Heart Rhythm,2020,doi:10.1016/j.hrthm.2020.05.008．
• [47]王慧珍，杨宝峰，罗大力，等．青蒿素抗心律失常作用的研究[J]．中国药理学通报，1998,14(1):3．
• [48]杨宝峰，徐长庆，李玉荣，等．青蒿素对克隆的内向整流钾通道的抑制作用(英文)[J]．中国药理学与毒理学杂志，1999,13(4):3．
• [49]史钰芳，杨靖，苗思露．青蒿素对心衰兔心功能及窦房结功能的影响[J]．中国中医药科技，2020,27(1):31．
• [50]GU Y,WU G,WANG X,et al.Artemisinin prevents electric remodeling following myocardial infarction possibly by upregulating the expression of connexin 43[J].Mol Med Rep,2014,10(4):1851．
• [51]XU X,ZHANG Q,SONG H,et al.Effects of artemisinin on ventricular arrhythmias in response to left ventricular afterload increase and microRNA expression profiles in Wistar rats[J].Peer J,2018,6:e6110．
• [52]REID B G,STRATTON M S,BOWERS S,et al.Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput,high content imaging[J].J Mol Cell Cardiol,2016,97:106．
• [53]XIONG Z,SUN G,ZHU C,et al.Artemisinin,an anti-malarial agent,inhibits rat cardiac hypertrophy via inhibition of NF-κBsignaling[J].Eur J Pharmacol,2010,649(1/3):277．
• [54]GU Y,WANG X,WANG X,et al.Artemisinin attenuates postinfarct myocardial remodeling by down-regulating the NF-κB pathway[J].Tohoku J Exp Med,2012,227(3):161．
• [55]GU Y,WANG X,WU G,et al.Artemisinin suppresses sympathetic hyperinnervation following myocardial infarction via anti-inflammatory effects[J].J Mol Histol,2012,43(6):737．
• [56]孙丽红，李鸿珠，韩丽萍，等．青蒿素对离体大鼠心肌缺血/再灌注损伤的保护作用[J]．中国中药杂志，2007,37(15):1547．
• [57]KHAN A I,KAPOOR A,CHEN J,et al.The antimalarial drug artesunate attenuates cardiac injury in a rodent model of myocardial infarction[J].Shock,2018,49(6):675．
• [58]宋爱新，王璐，张媛媛．青蒿素对心肌梗死大鼠心室重构的作用研究[J]．中国临床药理学杂志，2020,36(10):1233．
• [59]马瑞松，江洪，李元红，等．青蒿素抑制心肌缺血再灌注中的细胞凋亡[J]．现代医学，2016,44(7):919．
• [60]LIN SP,LI W,WINTERS A,et al.Artemisinin prevents glutamate-induced neuronal cell death via Akt pathway activation[J].Front Cell Neurosci,2018,12:108．
• [61]ZHENG W,CHONG C M,WANG H,et al.Artemisinin conferred ERK mediated neuroprotection to PC12 cells and cortical neurons exposed to sodium nitroprusside-induced oxidative insult[J].Free Radic Biol Med,2016,97:158．
• [62]LU H,WANG B,CUI N,et al.Artesunate suppresses oxidative and inflammatory processes by activating Nrf2 and ROS-dependent p38 MAPK and protects against cerebral ischemiareperfusion injury[J].Mol Med Rep,2018,17(5):6639．
• [63]ZUO S,GE H,LI Q,et al.Artesunate protected blood-brain barrier via sphingosine 1 phosphate receptor 1/phosphatidylinositol 3kinase pathway after subarachnoid hemorrhage in rats[J].Mol Neurobiol,2017,54(2):1213．
• [64]SHAO M,SHEN Y,SUN H,et al.Protectiveness of artesunate given prior ischemic cerebral infarction is mediated by increased autophagy[J].Front Neurol,2018,9:634．
• [65]JIANG W,CEN Y,SONG Y,et al.Artesunate attenuated progression of atherosclerosis lesion formation alone or combined with rosuvastatin through inhibition of pro-inflammatory cytokines and pro-inflammatory chemokines[J].Phytomedicine,2016,23(11):1259．
• [66]WANG Y,HUANG Z,WANG L,et al.The anti-malarial artemisinin inhibits pro-inflammatory cytokines via the NF-κB canonical signaling pathway in PMA-induced THP-1 monocytes[J].Int J Mol Med,2011,27(2):233．
• [67]JIANG Y,DU H,LIU X,et al.Artemisinin alleviates atherosclerotic lesion by reducing macrophage inflammation via regulation of AMPK/NF-κB/NLRP3 inflammasomes pathway[J].J Drug Target,2020,28(1):70．
• [68]YIN J,XIA W,ZHANG Y,et al.Role of dihydroartemisinin in regulating prostaglandin E2 synthesis cascade and inflammation in endothelial cells[J].Heart Vessels,2018,33(11):1411．
• [69]CAO Q,DU H,FU X,et al.Artemisinin attenuated atherosclerosis in high-fat diet-fed ApoE-/-mice by promoting macrophage autophagy through the AMPK/m TOR/ULK1 pathway[J].J Cardiovasc Pharmacol,2020,75(4):321．
• [70]CAO Q,JIANG Y,SHI J,et al.Artemisinin inhibits the proliferation,migration,and inflammatory reaction induced by tumor necrosis factor-alpha in vascular smooth muscle cells through nuclear factor kappa B pathway[J].J Surg Res,2015,194 (2):667．
• [71]WANG Y,CAO J,FAN Y,et al.Artemisinin inhibits monocyte adhesion to HUVECs through the NF-κB and MAPK pathways in vitro[J].Int J Mol Med,2016,37(6):1567．
• [72]LEE K P,PARK E S,KIM D E,et al.Artemisinin attenuates platelet-derived growth factor BB-induced migration of vascular smooth muscle cells[J].Nutr Res Pract,2014,8(5):521．
• [73]JANG S,JEONG M H,LIM K S,et al.Effect of stents coated with artemisinin or dihydroartemisinin in a porcine coronary restenosis model[J].Korean Circ J,2017,47(1):115．
• [74]DU H,ZHAO Q,ZANG H,et al.Artemisinin attenuates the development of atherosclerotic lesions by the regulation of vascular smooth muscle cell phenotype switching[J].Life Sci,2019,237:116943
• [75]WANG Y L,WANG Z J,SHEN H L,et al.Effects of artesunate and ursolic acid on hyperlipidemia and its complications in rabbit[J].Eur J Pharm Sci,2013,50(3-4):366．
• [76]WHITE N J.Cardiotoxicity of antimalarial drugs[J].Lancet Infect Dis,2007,7(8):549．
• [77]昆明医学院附属第一、第二医院疟疾防治组．青蒿素治疗疟疾的临床研究[J]．新医药学杂志，1979,20(2):49．
• [78]李敏，张乐曙，周洁茹，等．青蒿素和胺碘酮对大鼠心律失常作用的对比研究[J]．重庆医学，2020,49(6):883．
• [79]AI J,GAO H H,HE S Z,et al.Effects of matrine,artemisinin,tetrandrine on cytosolic[Ca2+]i in guinea pig ventricular myocytes[J].Acta Pharmacol Sin,2001,22(6):512．
• [80]HARA Y,YAMAWAKI H,SHIMADA M,et al.Anticholinergic effects of artemisinin,an antimalarial drug,in isolated guinea pig heart preparations[J].J Vet Med Sci,2007,69(7):697．
• [81]CHAN X H S,WIN Y N,MAWER L J,et al.Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria:a systematic review and Bayesian meta-analysis[J].Lancet Infect Dis,2018,18(8):913．
• [82]MYTTON O T,ASHLEY E A,PETO L,et al.Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria[J].Am J Trop Med Hyg,2007,77(3):447．
• [83]CHOTSIRI P,WATTANAKUL T,HOGLUND R M,et al.Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers[J].Br J Clin Pharmacol,2017,83(12):2752．
• [84]MILLAT-MARTINEZ P,ILA R,LAMAN M,et al.Electrocardiographic safety of repeated monthly dihydroartemisinin-piperaquine as a candidate for mass drug administration[J].Antimicrob Agents Chemother,2018,62(12):e01153．
• [85]KARBWANG J,LAOTHAVORN P,SUKONTASON K,et al.Effect of artemether on electrocardiogram in severe falciparum malaria[J].Southeast Asian J Trop Med Public Health,1997,28(3):472．
• [86]BADSHAH A,HAIDER I,SULEMAN S.Analytic study in patients presenting to a tertiary care hospital regarding the artemether-lumefantrine induced qtc interval changes in ECG[J].J Ayub Med Coll Abbottabad,2017,29(1):33．
• [87]BINDSCHEDLER M,LEFVRE G,DEGEN P,et al.Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants[J].Am J Trop Med Hyg,2002,66(3):293．
• [88]KRUDSOOD S,LOOAREESUWAN S,WILAIRATAMA P,et al.Effect of artesunate and mefloquine in combination on the Fridericia corrected QT intervals in Plasmodium falciparum infected adults from Thailand[J].Trop Med Int Health,2011,16 (4):458．
• [89]GUPTA R K,VAN VUGT M,PAIPHUN L,et al.Short report:no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate[J].Am J Trop Med Hyg,2005,73(2):267．
• [90]SEHAILIA M,CHEMAT S.In-silico studies of antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353and Lys31-binding hotspots of 2019-nCoV spike protein than hydroxychloroquine:potential repurposing of artenimol for COV-ID-19[J].Chem Rxiv,doi:10.26434/chemrxiv.12098652.v1．
• [91]CHEONG D H J,TAN D W S,WONG F W S,et al.Anti-malarial drug,artemisinin and its derivatives for the treatment of respiratory diseases[J].Pharmacol Res,2020,158:104901．
• [92]KATJA S.Artemisia annua to be tested against COVID-19[EB/OL].(2020-04-08)[2020-07-29].https://research-news.org/2020/04/08/artemisia-annua-to-be-tested-against-covid-19．
• [93]WAN S,YI Q,FAN S,et al.Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)[J].Med Rxiv,2020,doi:10.1101/2020.02.10.20021832．
• [94]TUFAN A,AVANOGLU GULER A,MATUCCI-CERINIC M.COVID-19,immune system response,hyperinflammation and repurposing antirheumatic drugs[J].Turk J Med Sci,2020,50(SI-1):620．
• [95]SAKAGUCHI S,YAMAGUCHI T,NOMURA T,et al.Regulatory T cells and immune tolerance[J].Cell,2008,133(5):775．
• [96]SAKAGUCHI S,MIYARA M,COSTANTINO C M,et al.FOXP3+regulatory T cells in the human immune system[J].Nat Rev Immunol,2010,10(7):490．
• [97]SALLUSTO F,LENIG D,FORSTER R,et al.Two subsets of memory T lymphocytes with distinct homing potentials and effector functions[J].Nature,1999,401(6754):708．
• [98]闫思超，李玉洁，王娅杰，等．青蒿素类药物对T细胞免疫调节作用研究进展[J]．中国中药杂志，2019,44(22):4992．
• [99]吴言为．青蒿素衍生物SM934对系统性红斑狼疮的疗效及作用机制研究[D]．上海:中国科学院上海药物研究所，2016．
• [100]常杰，李忱，张文．青蒿、青蒿素及其衍生物治疗系统性红斑狼疮研究现状[J]．中国中西医结合杂志，2019,39(3):377．
• [101]HOU L F,HE S J,LI X,et al.SM934 treated lupus-prone NZB×NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development[J].PLoS ONE,2012,7(2):e32424．
• [102]HOU L F,HE S J,LI X,et al.Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses[J].Arthritis Rheum,2011,63(8):2445．
• [103]占敏霞，杜伟，李恒华，等．双氢青蒿素与火把花配伍对迟发型超敏反应模型小鼠p-p38 MAPK及ICAM-1表达的影响[J]．中国中药杂志，2020,45(22):5561．
• [104]SHI C,LI H,YANG Y,et al.Anti-inflammatory and immunoregulatory functions of artemisinin and its derivatives[J].Mediators Inflamm,2015,2015:435713．
• [105]LI B,ZHANG R,LI J,et al.Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4,TLR9 mRNA expressions and transcription factor NF-kappa B activation[J].Int Immunopharmacol,2008,8(3):379．
• [106]LI B,LI J,PAN X,et al.Artesunate protects sepsis model mice challenged with Staphylococcus aureus by decreasing TNF-αrelease via inhibition TLR2 and Nod2 mRNA expressions and transcription factor NF-κB activation[J].Int Immunopharmacol,2010,10(3):344．
• [107]曹红卫，郭毅斌，魏利召，等．青蒿素对脓毒症大鼠肝脏脂质过氧化损伤的影响[J]．中国临床药理学与治疗学，2006,11(8):911．
• [108]KUANG M,CEN Y,QIN R,et al.Artesunate attenuates proinflammatory cytokine release from macrophages by inhibiting TLR4-mediated autophagic activation via the TRAF6-Beclin1-PI3KC3 pathway[J].Cell Physiol Biochem,2018,47(2):475．
• [109]HAMMING I,TIMENS W,BULTHUIS M,et al.Tissue distribution of ACE2 protein,the functional receptor for SARS coronavirus.A first step in understanding SARS pathogenesis[J].J Pathol,2004,203(2):631．
• [110]WANG L,ZHANG Z,LI M,et al.P53-dependent induction of ferroptosis is required for artemether to alleviate carbon tetrachloride-induced liver fibrosis and hepatic stellate cell activation[J].IUBMB life,2019,71(1):45．
• [111]ZHAO X,LIU M,LI J,et al.Antimalarial agent artesunate protects concanavalin A-induced autoimmune hepatitis in mice by inhibiting inflammatory responses[J].Chem Biol Interact,2017,274:116．
• [112]CHEN X,BIAN M,JIN H,et al.Dihydroartemisinin attenuates alcoholic fatty liver through regulation of lipin-1 signaling[J].IUBMB Life,2019,71:1740．
• [113]赵永伟，牛玉，何进田，等．双氢青蒿素对脂多糖诱导的断奶仔猪肝脏炎症以及脂代谢的影响[J]．中国中药杂志，2020,45(1):202．
• [114]CHEN Q,CHEN L,KONG D,et al.Dihydroartemisinin alleviates bile duct ligation-induced liver fibrosis and hepatic stellate cell activation by interfering with the PDGF-βR/ERK signaling pathway[J].Int immunopharmacol,2016,34:250．
• [115]CHEN Y X,LAI L N,ZHANG H Y,et al.Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis[J].World J Gastroenterol,2016,22(10):2949．
• [116]ROMERO M R,EFFERTH T,SERRANO M A,et al.Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an"in vitro"replicative system[J].Antiviral Res,2005,68(2):75．
• [117]PAESHUYSE J,COELMONT L,VLIEGEN I,et al.Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin[J].Biochem Biophys Res Commun,2006,348(1):139．
• [118]ROMERO M R,SERRANO M A,VALLEJO M,et al.Antiviral effect of artemisinin from Artemisia annua against a model member of the Flaviviridae family,the bovine viral diarrhoea virus(BVDV)[J].Planta Med,2006,72(13):1169．
• [119]KAPTEIN S J,EFFERTH T,LEIS M,et al.The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo[J].Antiviral Res,2006,69(2):60．
• [120]李明，刘洪江，崔向军．青蒿素类药物在非疟疾疾病中的研究进展[J]．中国全科医学，2018,21(12):1508．
• [121]欧利，秦克，杨子宵，等．双氢青蒿素对甲型流感病毒H1N1诱导人支气管上皮细胞TNF-α和IL-6表达的影响及机制研究[J]．四川大学学报:医学版，2020,51(2):171．
• [122]NAESENS L,BONNAFOUS P,AGUT H,et al.Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts[J].J Clin Virol,2006,37(Suppl 1):S69．
• [123]OIKNINE-DJIAN E,WEISBLUM Y,PANET A,et al.The artemisinin derivative artemisone is a potent inhibitor of human cytomegalovirus replication[J].Antimicrob Agents Chemother,2018,62(7):1．
• [124]PAESHUYSE J,COELMONT L,VLIEGEN I,et al.Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin[J].Biochem Biophys Res Commun,2006,348(1):139．
• [125]EFFERTH T,ROMERO M R,WOLF D G,et al.The antiviral activities of artemisinin and artesunate[J].Clin Infect Dis,2008,47(6):804．
• [126]袁蓉，信琪琪，唐仕欢，等．中医整体观指导下的COVID-19治疗---同时着眼于病毒和宿主的疗法[J]．中国中药杂志，2020,45(7):1521.